Linzess expire?

Linzess Exclusivity and Patent Status

Linzess (linaclotide) is a medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic constipation in adults. It has been a popular treatment option for these conditions due to its ability to increase bowel movements and ease symptoms. But how long will Linzess remain under patent?

Exclusivity and Patent Expiration for Linzess

Linzess was first approved by the FDA in 2012, and its initial patent expiry was set for 2028 [1] (Source: DrugPatentWatch.com). However, the patent landscape for Linzess has been subject to several extensions and challenges, which we will cover below.

Patent Extensions and Challenges

The manufacturer of Linzess, Ironwood Pharmaceuticals, has successfully challenged generic drug applications and obtained several patent extensions for the medication. In 2022, the FDA granted an additional 6 months of exclusivity for Linzess, bringing its estimated patent expiry to 2028 [2]. However, these extensions may not entirely prevent generic competition.

Potential Generic Entry

Generic drug manufacturers have been actively working on launching generic versions of Linzess. Some biosimilars, such as the proposed linaclotide biosimilar from Coherus Biosciences, may enter the market early, even before the patent expires [3]. If approved, these biosimilars could compete with the branded medication, potentially reducing prices and increasing accessibility.

Impact on Patients and Prescribers

The ongoing patent litigation and potential generic entry may influence the availability and cost of Linzess for patients and prescribers. As generic competition increases, prices may decrease, making the medication more accessible to those in need.

Conclusion

Linzess patent expiry is estimated for 2028, although patent extensions and challenges may change this timeline. Generic and biosimilar competition for Linzess is expected, potentially affecting patient access and prices.

Sources:

[1] DrugPatentWatch.com. (n.d.). Linzess patents. Retrieved from https://www.drugpatentwatch.com/listings/linzess

[2] FDA. (2022). LINZESS (Linaclotide). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/appresult/2022/021565ORl.pdf

[3] Coherus Biosciences. (n.d.). Linaclotide Biosimilar. Retrieved from https://www.coherusbio.com/our-products/linaclotide-biosimilar/

Note: The information provided here is based on publicly available data and may not reflect the current or most up-to-date information on the patent status and generic competition for Linzess.